Association between XXXX and @entity1082 detected by Hybrid Capture II assay.

@entity1 @entity13389 @entity5 @entity1721 @entity601 @entity1082
From July 1999 to July 2000, 40 @entity1 from the Surgical Oncology and Gastroenterology Departments of Irmandade da Santa @entity13389 de Miseric  rdia de Porto Alegre were enrolled in a prospective study in order to find the frequency of @entity1082 DNA (HPV-DNA) in @entity1721 . They were compared to 10 normal individuals (controls). Digene Inc. (Digene Corporation, Gaithersburg @entity601 , USA) Hybrid Capture II assay, a chemoluminescent method, was used in both groups. The samples were collected from the @entity5 group by endoscopic biopsy in 20 cases, and by surgical specimens in the other 20 cases; the control group all underwent endoscopic biopsies. The cut-off point in the analytical assay for HPV-DNA was 1.0 pg/mL. Digene Corp. Hybrid Capture II assay tests HPV-DNA and differentiates high and low-risk for malignization virus groups. Gender, age, location of the @entity5 in esophagus and degree of differentiation on histology were also analyzed. There was one positive case (1.14 pg/mL), a 2.5% frequency of low-risk HPV-DNA type in the @entity1721 group (CI 95%: 0.00-7.34%). This group of @entity1 consisted of 30 male and 10 female individuals, similar to the distribution seen in large series of such @entity1 from the Brazilian population. The mean age was 63 years. Endoscopic samples of 10 @entity1 who underwent endoscopic biopsy procedure for aleatory reasons, with normal looking esophageal mucosa, were tested to detect HPV-DNA, as controls. There was one positive case (1.17 pg/mL) of high-risk HPV-DNA type, resulting in a 10% positive rate. HPV-DNA is rarely found in @entity1721 : we found a 2.5% frequency, with confidence interval of 0-7.34%; and this is in the same range of controls (10% frequency, with CI: 9.1-10.9%). Both @entity1 had a viral load quite near the 1.0 pg/mL cut-off point.
